Hib-DTP-hepatitis B vaccine(Panacea Biotec Ltd.)

The FDA has approved a new Pfizer meningococcal vaccine whose simpler dosing schedule is expected to make it easier for children and young adults to get fully vaccinated to protect against a rare infection that can quickly become fatal within 24 hours. Five groups of Neisseria meningitidis bacteria are the most common cause of meningococcal disease, which causes infections of the lining of the brain and spinal cord as well as the blood. For those who survive serious cases of the infection, the effects can still be long lasting. Pfizer already had four of the culprit bacterial groups covered with a vaccine called Nimenrix. Another Pfizer vaccine called Trumenba covers the fifth group of bacteria. Penbraya, the meningococcal vaccine approved by the FDA on Friday, combines Nimenrix and Trumenba in a single shot. The regulatory decision covers use of this new vaccine in those ages 10 through 25. Penbraya is administered as two intramuscular injections given six months apart. Penbraya is a bacterial vaccine. It works by what’s called active immunization, in which the immune system is prompted to produce antibodies against target pathogens. FDA approval of the new Pfizer vaccine is based on the results of clinical trials that compared Penbraya to currently available meningococcal vaccines. Results showed this vaccine was “noninferior,” meaning it was not worse at eliciting an immune response versus the comparator vaccines. “In a single vaccine, Penbraya has the potential to protect more adolescents and young adults from this severe and unpredictable disease by providing the broadest meningococcal coverage in the fewest shots,” Annaliesa Anderson, senior vice president and head, vaccine research and development at Pfizer, said in a prepared statement. The Phase 3 study for Penbraya enrolled more than 2,400 patients from the U.S. and Europe. The most common adverse reactions were pain at the injection site, fatigue, headache, injection site redness, muscle pain, injection site swelling, joint pain, and chills. The vaccine’s label also cautions that Guillain-Barré syndrome, an immune response that damages nerves, has been reported after dosing of other meningococcal vaccines. The next step for Penbraya is a recommendation from the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices. This vaccine is the first agenda item for the committee’s next meeting, scheduled for this Wednesday. Pfizer isn’t the only company trying to offer protection against meningococcal infection with fewer shots. GSK’s pentavalent meningococcal vaccine candidate is a combination of that company’s approved vaccines, Bexsero and Menveo. In March of this year, the British pharmaceutical giant reported Phase 3 results showing this vaccine candidate, administered as two doses six months apart, was non-inferior to the two approved GSK meningococcal vaccines.

The FDA on Friday approved Pfizer's pentavalent meningococcal vaccine Penbraya for adolescents and young adults ages 10 through 25 years. Penbraya, which combines the components of Pfizer's Trumenba (meningococcal group B vaccine) and Nimenrix (meningococcal groups A, C, W-135, and Y conjugate vaccine), becomes the first vaccine cleared to prevent the five most common serogroups causing meningococcal disease."In a single vaccine, Penbraya has the potential to protect otherwise healthy adolescents and young adults from this severe and unpredictable disease by providing the broadest meningococcal coverage in the fewest shots," commented Annaliesa Anderson, Pfizer's head of vaccine R&D.The company's submission was supported by results from a randomised Phase III trial comparing Penbraya against currently licensed meningococcal vaccines in more than 2400 participants. Last year, Pfizer reported that the trial succeeded on all of its primary and secondary endpoints. Specifically, Penbraya was found to be non-inferior to licensed vaccines in the US for all five of the serogroups that cause the majority of invasive meningococcal disease. A single dose of Penbraya also met non-inferiority criteria for serogroups A, C, W and Y compared to one dose of GSK's Menveo.Earlier this year, GSK reported that its own pentavalent meningococcal vaccine candidate met all primary endpoints in a Phase III study, including non-inferiority to Menveo, which protects against meningococcal groups A, C, Y and W-135, and the company's licensed meningococcal B vaccine Bexsero.An advisory panel to the US Centers for Disease Control and Prevention (CDC) is set to meet on October 25 to discuss recommendations for the appropriate use of Penbraya in adolescents and young adults.